Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Stock Information for P3 Health Partners Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About P3 Health Partners Inc.

Mdxhealth Reports Q1-2026 Results
Mdxhealth to Release First Quarter 2026 Financial Results on May 13
Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025
Mdxhealth to Release Third Quarter 2025 Financial Results on November 12

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.